COMPENSATIONINFORMATION FOR NAMED EXECUTIVE OFFICERS
EXHIBIT 10.20
COMPENSATION INFORMATION FOR NAMED EXECUTIVE OFFICERS
The table below provides information regarding the discretionary cash bonus and cash incentive payments paid for performance in the year ended December 31, 2007, as well as the 2008 annual base salary and target percentage for a cash incentive payment for performance in 2008, of each named executive officer of ARYx Therapeutics, Inc. (the “Company”).
| Name and Principal Position |
| 2007 Bonus(1) |
| 2007 Non-Equity |
| 2008 Annual |
| 2008 Target Cash Incentive |
| |||
| Paul Goddard, Ph.D. |
| $ | 40,000 |
| $ | 200,000 |
| $ | 437,850 |
| 50.0 | % |
| Chairman and Chief Executive Officer |
|
|
|
|
|
|
|
|
| |||
| Peter G. Milner, M.D. |
| — |
| $ | 80,000 |
| $ | 322,857 |
| 30.0 | % | |
| President, Research and Development |
|
|
|
|
|
|
|
|
| |||
| John Varian |
| — |
| $ | 70,000 |
| $ | 314,773 |
| 25.0 | % | |
| Chief Operating Officer and Chief Financial Officer |
|
|
|
|
|
|
|
|
| |||
| Pascal Druzgala, Ph.D. |
| — |
| $ | 60,000 |
| $ | 262,463 |
| 25.0 | % | |
| Vice President and Chief Scientific Officer |
|
|
|
|
|
|
|
|
| |||
| Daniel Canafax, Pharm.D. |
| — |
| $ | 45,000 |
| $ | 263,288 |
| 25.0 | % | |
| Vice President and Chief Development Officer |
|
|
|
|
|
|
|
|
| |||
| David Nagler |
| — |
| $ | 55,000 |
| $ | 249,223 |
| 25.0 | % | |
| Vice President, Corporate Affairs and Secretary |
|
|
|
|
|
|
|
|
|
|
| |
(1) Represents a discretionary cash bonus paid by the Company for performance in 2007.
(2) Represents cash incentive payments based on the achievement of performance goals or milestones established by the Compensation Committee of the Board of Directors of the Company in February 2007.
